Pre Test - Seeing Presbyopia in a New Light: Elevating Care with Contact Lenses, IOLs, Surgery, andPresbyopic Drops*This pre test is NOT required unless your state board requires one for CE credit. Please check with your individual state board. Name * First Name Last Name Email License State and Number In a study of 1,000 presbyopes, how did consumers rank the loss of near vision in terms of its impact on quality of life compared to other age-related ailments? #1 impact on quality of life #3 impact on quality of life #10 impact on quality of life #100 impact on quality of life Treatment options for presbyopia include all of the following except Spectacles Contact Lenses Surgical options Pharmaceutical eye drop options Pharmaceutical nasal options All of the following are contact lens options for presbyopia except Multifocal contact lenses Modified monovision Distance glasses and reading glasses Monovision contact lenses Key considerations when evaluating pharmacological agents for presbyopia include Cost being the primary differentiating factor Assessing efficacy, duration of action, and adverse events/side effects Ensuring only binocular vision outcomes (not monocular) are reported The packaging design should be visually appealing The primary endpoint used in clinical trials for miotic presbyopia agents is: The % of subjects achieving 20/15 near vision The number of satisfied patients after using the drop The % of patients experiencing headache The % of subjects achieving an equal to or greater than 3 line (15 letter) improvement in distance corrected near vision measured under mesopic illumination (statistical difference from the control) The first FDA-approved pharmaceutical for presbyopia is 1.25% Pilocarpine 0.4% Pilocarpine Carbachol 2.75% / Brimonidine tartrate 0.1% 0.75% Phentolamine A pupil-selective miotic is preferred for treating presbyopia and reducing visual aberrations because: It is far less costly than a non-selective miotic It stings less upon insertion. It optimally reduces pupil size appropriately without significant ciliary muscle stimulation and its resulting undesirable side effects It has less effect on iris color changes Which of the following best describes the primary indication for additional lens implantation in pseudophakic patients? To reduce glare and halos caused by IOL-light interactions To provide a wider range of vision than the current IOL allows Reserved for pseudophakic patients with highly aberrated corneas To improve cosmetic appearance of the eye Which of the following is considered an IOL technology for presbyopia management? Sulcus-based Small-aperture Monovision Prior authorization Small aperture / pinhole optics enhance visual performance by: (A: d) Reversing miosis Stimulating the ciliary muscle Increasing high order aberrations Extending both depth of focus and depth of field Thank you submitting your responses. They have been recorded. Please email us if you need a copy for your state board.
